Talking Biotech, Microsoft Discovery, and conversation-led GTM

Most founders think of a podcast as content marketing. I treated it as a sales channel.

I acquired Talking Biotech and repositioned it toward the commercial side of biopharma. The innovation was in the format. I ran 15 to 30 minute pre-interviews to vet potential panelists, and those pre-interviews *were* the sales-relevant meetings. Even guests who never ended up recording gave me qualification, pain discovery, and a warm follow-up path. In a three-week window, that process put me in direct conversation with John Howie (M&A, Bayer), Ray Letulle (product, Veeva), Bodo Marr (M&A treasury, Morphosys), Mitul Shah (product, Thermo Fisher), and Justin Pront and Bruce Upbin at Tetrascience. These were framed as podcast panel vetting calls, not sales calls. That is the distinction. It was not "host a podcast to get guests." It was "use the pre-interview as the meeting."

Separately, Colabra was selected as one of roughly five ISV partners in the Microsoft Discovery program. I ran recurring joint sessions with a Microsoft team of six to seven people over four months: Bella Chan, Ali Zaman, Mukesh Dua, Karthik Ananthakrishnan, Nihit Pokhrel. The work covered technical integration architecture, sandbox access timelines, demo video production for Ignite, and marketing review processes.

Then Microsoft went through layoffs that hit the Discovery BD team directly. Sandbox access was delayed from late July to mid-August, then further out. I tracked the slippage, escalated with Bella, and assessed where Colabra sat in their resource prioritization among the ISV partners. The September investor update said it plainly: "One of a handful of companies selected for the Microsoft Discovery partner program. Decision: maintain relationship; do not depend on channel for revenue." That was the right call. A founder has to be able to tell the difference between a real channel and wishful thinking dressed up as strategy.